Ifosfamide urotoxic metabolites

Ifosfamide urotoxic metabolites, primarily acrolein and chloroacetaldehyde, are reactive chemical byproducts generated during the hepatic metabolism of the alkylating chemotherapy agent ifosfamide (StatPearls, NBK499932). While the ifosfamide mustard metabolite provides the intended therapeutic anti-tumor effect by cross-linking DNA, acrolein is concentrated in the urine where it causes direct oxidative damage and sloughing of the bladder epithelium (PubMed, 3089134). This process leads to hemorrhagic cystitis, a severe and potentially dose-limiting complication of therapy. Chloroacetaldehyde, another significant metabolite produced via side-chain dechloroethylation, is associated with nephrotoxicity and central nervous system toxicity, including encephalopathy (PubChem, CID 6561). These metabolites are the primary pharmacological targets for the chemoprotective drug Mesna (sodium 2-mercaptoethanesulfonate), which is administered concurrently with ifosfamide. Mesna provides a free thiol group that undergoes a Michael addition with acrolein in the urinary tract, forming a stable, non-toxic thioether conjugate that is safely excreted (FDA Label, Ifex). Effective management of these metabolites is essential to prevent dose-limiting toxicities during high-dose ifosfamide therapy. Monitoring for hematuria and ensuring adequate hydration are standard clinical practices to mitigate the risks associated with these metabolites.

Other names

AcroleinChloroacetaldehyde2-propenalCAAUrotoxic ifosfamide byproducts

Chemical neutralization via nucleophilic conjugation (Michael addition) with thiol-containing compounds to form stable, non-toxic thioethers (StatPearls, NBK499932).